Skip to main content
Retour
Watch Compare

C4 Therapeutics, Inc.

Qualité des données : 100%
CCCC
NASDAQ Manufacturing Chemicals
2,74 €
▲ 0,20 € (8,05%)
Cap. Boursière: 247,36 M
Prix
2,54 €
Cap. Boursière
247,36 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -99,30 M
Capital efficient — spends only 1,69% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)1,02%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-63,93%
En dessous de la moyenne du secteur (-54,01%)
ROIC-37,80%
Net Margin-292,08%
Op. Margin-320,53%

Sécurité

Debt / Equity
N/A
Current Ratio5,76
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-2,36 | -2,07
En dessous de la moyenne du secteur (-1,49)
P/B Ratio1,60
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -2,4 -1,5
P/B 1,6 1,6
ROE % -63,9 -54,0
Net Margin % -292,1 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

7 analystes
Buy
Actuel
2,74 €
+322.5%
Objectif
11,57 €
6,00 €
7,00 €
30,00 €
Prévisions
P/E Prévisionnel -2,07
BPA Prévisionnel -1,23 €
CA Est. 21,62 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -1,23 €
-1,45 € – -0,98 €
 21,62 M 4
FY2026 -1,10 €
-1,15 € – -0,99 €
 21,62 M 3

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,39 € -0,18 € +54,2%
Q32025 -0,39 € -0,30 € +24,6%
Q22025 -0,38 € -0,37 € +3,3%
Q12025 -0,43 € -0,37 € +13,6%

ETFs Holding This Stock

MSGGX MSGGX
0,23% weight
MISGX MISGX
0,23% weight
MSGAX MSGAX
0,23% weight
MSGRX MSGRX
0,23% weight
MSGCX MSGCX
0,23% weight
BRSIX BRSIX
0,20% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 1,02% Revenue Growth (3Y) 31,60%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 35,95 M Net Income (TTM) -104,99 M
ROE -63,93% ROA -37,36%
Gross Margin N/A Operating Margin -320,53%
Net Margin -292,08% Free Cash Flow (TTM) -99,30 M
ROIC -37,80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,76
Interest Coverage N/A Asset Turnover 0,13
Working Capital 170,92 M Tangible Book Value 154,41 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,36 Forward P/E -2,07
P/B Ratio 1,60 P/S Ratio 6,88
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 11,44 Fwd Earnings Yield N/A
FCF Yield -40,14%
Market Cap 247,36 M Enterprise Value 188,55 M
Per Share
EPS (Diluted TTM) -1,27 Revenue / Share 0,37
FCF / Share -1,02 OCF / Share -1,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,69% FCF Conversion 94,58%
SBC-Adj. FCF -135,27 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 35,95 M 35,58 M 20,76 M 31,10 M —
Net Income -104,99 M -105,32 M -132,49 M -128,18 M -83,89 M
EPS (Diluted) -1,27 -1,52 -2,67 -2,62 —
Gross Profit — — — — —
Operating Income -115,22 M -119,61 M -139,03 M -129,53 M -82,13 M
EBITDA — — — — —
R&D Expenses 104,24 M 110,64 M 117,71 M 117,84 M 94,67 M
SG&A Expenses — — — — —
D&A 1,96 M 1,82 M 1,88 M 1,68 M 1,49 M
Interest Expense — — — — —
Income Tax 121 000,0 131 000,0 1,28 M 0,0 -626 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 359,08 M 349,60 M 376,45 M 430,84 M 506,77 M
Total Liabilities 102,49 M 133,62 M 130,34 M 141,61 M 117,16 M
Shareholders' Equity 256,59 M 215,99 M 246,11 M 289,23 M 389,61 M
Total Debt — — 11,48 M 11,48 M 10,77 M
Cash & Equivalents 74,60 M 55,50 M 126,59 M 29,75 M 76,12 M
Current Assets 258,11 M 257,77 M 271,19 M 287,56 M 325,69 M
Current Liabilities 33,03 M 45,18 M 42,77 M 44,55 M 51,25 M